Last, we explored whether we could see consistent direction of effect in a further independent cohort of genotyped patients receiving ICB for cancer obtained post–primary analysis where we had pretreatment CD8 TCR mapped from RNA-seq data (n = 34). This evidence concerns the gene CD8A and cancer.